Accordingly, neutralizing antibodies against IL-4 and IL-13, as well as a Stat6 inhibitor, significantly retarded the proliferation of CD4+ T cells isolated from leukemic CTCL patients [41]. This evidence concerns the gene STAT6 and primary cutaneous T-cell non-Hodgkin lymphoma.